Background: The protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) has proven in several studies an active and well tolerated treatment for advanced, pretreated breast cancer. Navelbine has also activity in this setting.
Introduction
Although metastatic breast cancer remains an incurable disease, several advances in its management have been made in recent years, including new hormonal treatments, chemotherapy agents and monoclonal antibodies. The issues of toxicity and convenience of administration are of importance in the palliative setting.
The protracted continuous infusion (PCI) of 5-fluorouracil (5-FU) is based upon a sound rationale [1] and has been evaluated in some tumour types with interesting results in terms of activity and lack of relevant toxicity besides some partly specific, transient toxic effects (i.e., hand-foot syndrome and mucositis). In particular, a 21%-53% response rate was reported in metastatic breast cancer in phase II studies [2] [3] [4] [5] . Navelbine (NVB) is a drug with well known activity in metastatic breast cancer (6) and a toxicity (mainly bone marrow and neurotoxicity) not ovelapping with that of PCI-5-FU. In 1998 we activated a study aimed to evaluate the combination of PCI-5-FU and NVB in a consecutive series of patients with metastatic breast cancer. The early results of that study are the subject of the present report.
Patients and methods
From February 1998 to December 1999 all eligible patients presenting at our Institution were considered for the study. Eligibility criteria included histologically proven adenocarcinoma of the breast, metastatic disease, Karnofsky performance status greater than 40, hormone resistant disease, progressive disease while on chemotherapy, resistance to anthracyclines (adriamycin or epirubicin) or contraindication to anthracyclines, measurable or evaluable disease, no previous PCI-5-FU or NVB, absence of brain metastases, white blood cell counts greater than 4000/ul and platelet counts greater than 120,000/ul, serum bilirubin less than 2 mg/dl, permanent venous access feasible. Written informed consent was obtained prior to central venous catheter insertion. Treatment consisted of 5-FU 250 mg/m 2 /day given as a continuous infusion by means of an elastomeric pump (Seven Day Infusor 0.5 ml/h, Baxter) via an indwelling Groshong catheter. In addition, NVB 20 mg/m 2 administered as a 30-45" infusion in 100 ml of normal saline was administered on day 1 and 8, every four weeks (one cycle). Both drugs were administered until progression or prohibitive toxicity. Complete blood cell counts were obtained on day I, 8 and 15. The infusion of 5-FU was discontinued until recovery in the event of grade 4 bone marrow toxicity and grade 3-4 hand-foot syndrome or mucositis. Grade 0 bone marrow toxicity was required to start a new NVB cycle, otherwise NVB was delayed until recovery. In the event of grade 1 toxicity on day 8, half dose of NVB was administered, while for lesser counts NVB was not given. Hematologic growth factors were not planned. The criteria for response were those described by Miller [7] , while toxicity was classified according to the Common Toxicity Criteria of the National Cancer Institute. Actuarial curves were plotted according to the Kaplan-Meier method [8] . Table I . Patient characteristics. The distribution of various characteristics in the whole patient population and in responding patients is reported in separate columns.
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Results
In the study period, 83 patients entered the study. Their main characteristics are described in Table 1 . Median age was 54 years, ranging from 32-82 years. Median Karnofsky performance status was 80 (range 50-100). The median number of metastatic tumour sites was 2 (range 1-4). Soft tissues (lymph nodes, skin) were the dominant metastatic site in 21 patients, lung in 10, bone in 18, liver in 28, and serosal cavities in 6 patients, respectively. The median number of chemotherapy lines in the metastatic phase was 2 (range 0-5), including anthracyclines (mostly epirubicin) in 52 patients and taxanes in 29. In addition, 38 patients had received chemotherapy in the adjuvant phase, including anthracyclines in 36 patients and taxanes in 2. Only five patients were unpretreated with anthracyclines. Seventyfour patients had received bolus 5-FU as part of combination chemotherapy (CMF, FEC). All patients with hormone sensitive tumors had been pretreated with several lines of hormonal treatment both in the metastatic and in the adjuvant phase.
A total number of 454 chemotherapy cycles were administered to the 83 patients entered into the study (median 5, range [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The median relative dose intensity was 92% for 5-FU and 97% for NVB. The median duration of PCI-5-FU was 17 weeks (range 4-90 weeks). Seven patients discontinued NVB due to neurotoxicity or persistent bone marrow toxicity and continued with PCI -5-FU alone for a median of 12 additional weeks (range 4-40 weeks). Three patients are not yet evaluable. In the 80 evaluable patients, 12 complete remissions (15%) and 24 partial remissions (30%) were noted. Twelve additional patients had disease stabilization for more then two months. Response rate was 45% (95% confidence limits: 39%-51%). The characteristics of responding patients are reported in patients pretreated with taxanes, response rate was 28%.
Responses were noted at all disease sites. In particular, 9 out of 28 patients with liver metastases responded, with 4 complete remissions including 3 in patients pretreated with both anthracyclines and taxanes. Actuarial median duration of response was nine months. Actuarial median time to progression was six months. The toxic effects encountered are reported in Table 2 . Overall, toxicity was acceptable and consisted mainly of hand-foot syndrome and mucositis, both reversible upon discontinuation of PCI-5-FU. No evident hair loss was observed. Two cases of possible cardiotoxicity (one case of angina and one case of myocardial infarction) occurred, requiring discontinuation of chemotherapy. In the first case, after five months' discontinuation PCI-5-FU and NVB were resumed without recurring of cardiac symptoms and with 7+ months' additional survival, while in the second the patient remained off chemotherapy and died nine months after the myocardial infarction due to progressive disease. Four catheters had to be removed due to local infection and one due to subclavian thrombophlebitis. No other case of clinically evident thrombophlebitis was noted. No toxic deaths occurred. With 46 patients still alive, actuarial median survival is 20 months.
Discussion
Following to the original report by Lokich et al. [9] on the PCI of 5-FU in advanced colorectal cancer, several groups have investigated this treatment modality in colorectal and breast cancer. The interest in the PCI of 5-FU was based on its capacity to circumvent cell resistance through the continuous exposure to the drug of tumour cells in turn entering the tipically 5-FU sensitive S phase and to obtain effective plasma concentrations for long periods of time [5] . Breast cancer appears to be a good candidate for the PCI of 5-FU due to its frequent chronic course requiring successive lines of treatment, to the activity of 5-FU in conventional schedules in this disease, and to the frequent indication to relatively mild and well tolerated treatments in patients heavily pretreated, during long periods of time, with several lines of intensive chemotherapy. The availability of taxanes in the medical oncologist's armamentarium has increased the size of the latter population of patients.
Based on these considerations, we devised a drug combination incorporating CI-5-FU at a dosage previously evaluated by several studies, including one at our Institution [10] , and NVB with reduced dosage as compared to single-agent schedules. The choice of NVB was based on its activity as a single agent [14] , on its different mechanism of action and on its spectrum of toxicity, which does not in general overlap that of PCI-5-FU. The anticipated lack of hair loss was considered important for the patient population eligible for the study. In view of the palliative intent of the treatment and of the heavy pretreatment, NVB dosage was attenuated to 20 mg/irr on day 1 and 8, every four weeks in order to prevent 5-FU discontinuation due to severe neutropenia.
The results obtained, with a 45% response rate (28% in patients pretreated with taxanes) and a median survival of 20 months, are encouraging taken into account the poor prognosis of the patient population studied, pretreated with a median of 2 lines of chemotherapy in the metastatic phase, including anthracyclines and /or taxanes in the vast majority of cases. The 28% response rate obtained in patients pretreated with taxanes appears noteworthy, as well as the occurrence of responses in 'difficult' sites. The toxicity noted was acceptable, the most relevant toxic effect being reversible hand-foot syndrome. In the evaluation of bone marrow suppression, it should be noted that complete blood counts were obtained, besides on the days NVB was scheduled, on day 15, yielding a number of cases of mild, asymptomatic leuko-thrombocytopenia not to be detected otherwise. Compliance to treatment was good, with no patient permanently discontinuing PCI of 5-FU due to drug toxicity or to logistic inconvenience. This was in line with a recent randomized study comparing elastomeric to electronic pumps in the PCI of 5-FU [11] . However, five patients had their catheter removed due to local infection or thrombophlebitis.
In addition to early reports [2, 5] , some additional phase II studies evaluating PCI-5-FU or PCI-5-FUbased combinations in advanced breast cancer have recently appeared [3, 4, 10] . In the most substantial series, Regazzoni et al. [3] reported a 21% response rate in 80 evaluable patients treated with PCI of 5-FU at the dosage of 250 mg/m /day, with one week's rest every four weeks. We previously observed a 33% response rate in 30 patients treated with PCI-5-FU 250 mg/m 2 continuously [10] . As regards combinations including PCI-5-FU, Smith et al. reported a high (98%) response rate with a combination of PCI-5-FU, epirubicin and cisplatin in the primary neoadjuvant setting [12] . Taxol combined with PCI-5-FU was evaluated with encouraging results [13] . NVB was associated to a short-term infusion of 5-FU with a high response rate in some studies [14, 15] . Although no direct comparison is possible between these different series, we think this body of studies lends support to a role of PCI-5-FU based chemotherapy in advanced breast cancer, in view of its activity, lack of relevant toxicity and logistic feasibility. Economic considerations also tend to favour this approach in comparison to intensive chemotherapy [3] . The eventual role of the regimen evaluated in this study, or of similar regimens, in less advanced phases of the disease appears worthy of evaluation in non randomized and randomized studies. Another important issue is the activity of the new oral fluoropyrimidines compared to that of PCI of 5-FU, with possible advances in the feasibility and convenience of treatment but also greater costs. These aspects are likely to be the object of active research in the next years.
